April 12, 2005
PEGASUS/HEARTVIEW CLINICAL TRIAL
FOR HEART DISEASE SCREENING DEVICE UNDERWAY IN NEW
note that the name of the Cardiovisor 6S System has
since been changed to HeartVue™ 6S System)
Palm Beach Gardens , Fla. - Business
Wire - April 12, 2005 . Pegasus Pharmaceuticals Inc.
(OTC-PGUZ) has acquired 51% of Heartview LLC, a Cleveland,
Heartview has developed a portable
heart screening device which provides physicians with
a faster, more accurate method for earlier detection
of heart diseases. The Cardiovisor 6S System conducts
an ECG data analysis and builds and displays a color-coded
topological portrait of heart electrical activity providing
principally new information about the heart state after
only 60 seconds. This faster, more portable device
has tremendous potential in cutting costs associated
with ischemic heart disease and for screening populations.
The Cardiovisor 6S heart screening
system is currently undergoing clinical trials at a
major hospital in New York , N.Y.
On behalf of the Board of Directors,
Dan Kesonen, Chairman & CEO,
For more information,
please contact Daniel P. Kesonen, Chairman & CEO
of Pegasus Pharmaceuticals Inc. at (561) 626-9901.